The Pharmaceutical Journal
Vol 280 No 7493 p301
15 March 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Lilly axes inhaled insulin

Eli Lilly and Company has terminated its inhaled insulin programme — AIR Insulin — a joint venture with Alkermes Inc.

The programme, currently in phase III, has been axed not because of safety concerns during trials, Lilly says, rather as “a result of increasing uncertainties in the regulatory environment, and a thorough evaluation of the evolving commercial and clinical potential of the product compared to existing medical therapies”.

Responding to the news, rival biopharmaceutical firm MannKind said it remained “absolutely committed” to its Technosphere Insulin product, which is in phase III trials.